Source:http://linkedlifedata.com/resource/pubmed/id/11369660
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
2001-5-22
|
| pubmed:abstractText |
The short-term beneficial effect of hydroxyurea (HU) in sickle cell disease (SCD) has been proven by randomized studies in children and adults. The Belgian registry of HU-treated SCD patients was created to evaluate its long-term efficacy and toxicity. The median follow-up of the 93 patients registered is 3.5 years; clinical and laboratory data have been obtained for 82 patients at 1 year, 61 at 2 years, 44 at 3 years, 33 at 4 years, and 22 after 5 years. On HU, the number of hospitalizations and days hospitalized dropped significantly. Analysis of the 22 patients with a minimum of 5 years of follow-up confirm a significant difference in the number of hospitalizations (P =.0002) and days in the hospital (P <.01), throughout the treatment when compared to prior to HU therapy. The probabilities of not experiencing any event or any vaso-occlusive crisis requiring hospitalization during the 5 years of treatment were, respectively, 47% and 55%. On HU, the rate per 100 patient-years of severe events was estimated to be 3.5% for acute chest syndrome, 1.2% for aplastic crisis, 0.4% for splenic sequestration; it was 0% for the 9 patients with a history of stroke or transient ischemic attack followed for an average of 4 years. No important adverse effect occurred. Long-term chronic treatment with HU for patients with SCD appears feasible, effective, and devoid of any major toxicity; in patients with a history of stroke, HU may be a valid alternative to chronic transfusion support. (Blood. 2001;97:3628-3632)
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:CorazzaFF,
pubmed-author:DevalckCC,
pubmed-author:DresseM FMF,
pubmed-author:FeremansWW,
pubmed-author:FersterAA,
pubmed-author:FonduPP,
pubmed-author:HunninckKK,
pubmed-author:PhilippetPP,
pubmed-author:SaribanEE,
pubmed-author:SturboisGG,
pubmed-author:TahririPP,
pubmed-author:ToppetMM,
pubmed-author:Van GeetCC,
pubmed-author:VermylenCC
|
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
97
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3628-32
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11369660-Acute Disease,
pubmed-meshheading:11369660-Adolescent,
pubmed-meshheading:11369660-Adult,
pubmed-meshheading:11369660-Anemia, Aplastic,
pubmed-meshheading:11369660-Anemia, Sickle Cell,
pubmed-meshheading:11369660-Antisickling Agents,
pubmed-meshheading:11369660-Arterial Occlusive Diseases,
pubmed-meshheading:11369660-Chest Pain,
pubmed-meshheading:11369660-Child,
pubmed-meshheading:11369660-Child, Preschool,
pubmed-meshheading:11369660-Female,
pubmed-meshheading:11369660-Hospitalization,
pubmed-meshheading:11369660-Humans,
pubmed-meshheading:11369660-Hydroxyurea,
pubmed-meshheading:11369660-Length of Stay,
pubmed-meshheading:11369660-Male,
pubmed-meshheading:11369660-Oxygen,
pubmed-meshheading:11369660-Registries,
pubmed-meshheading:11369660-Splenomegaly,
pubmed-meshheading:11369660-Stroke
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Five years of experience with hydroxyurea in children and young adults with sickle cell disease.
|
| pubmed:affiliation |
Hemato-Oncology Unit, Hôpital Universitaire des Enfants Reine Fabiola, Av J J Crocq, 15-1020 Brussels, Belgium.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|